27 results
8-K
EX-10.1
MRKR
Marker Therapeutics Inc
13 Dec 22
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
7:30am
, service mark registrations, trade secret or other infringement, which could reasonably be expected to have a Material Adverse Effect.
(l) Environmental … or contaminants ("Environmental Laws"), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws
8-K
EX-1.1
fey kzdlr
16 Mar 21
CORPORATE PRESENTATION March 2021
5:16pm
8-K
EX-10.1
av3dm
2 Mar 20
Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million
9:03am
PREM14A
yr45vycqlmh76di7f0fj
13 Jul 18
Preliminary proxy related to merger
5:16pm
8-K
EX-10.1
4txu39
8 Jun 18
TapImmune Announces Pricing of $70 Million Private Placement
9:21am
D
jwucmupyzw7v145
24 May 18
$3.1M in equity, sold $3.1M, 1 investor
4:03pm
8-K
EX-2.1
pjy0b dtk6w6px8
15 May 18
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
6:07am
DEFA14A
EX-2.1
a09anez9 qn9f
15 May 18
Additional proxy soliciting materials
6:05am
8-K
EX-10.1
st53ceu4y
12 Jan 15
Entry into a Material Definitive Agreement
12:00am
D
27s7edmdlac ce9az2a
2 Jun 10
$1.28M in equity / debt / options / securities to be acquired, sold $1.28M, 4 investors
12:00am
8-K
EX-10.1
itrct7lv
18 May 10
TapImmune Inc. Executes a Securities Purchase Agreement for the Issuance of $1.53 million in Convertible Debt
12:00am
8-K
EX-14.1
e5gm9sf7edykcxkxl
3 Dec 09
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
12:00am
D
qe6pv1afare88nu73
10 Nov 09
$350K in debt / options, sold $350K, 1 investor
12:00am